Coeptis Therapeutics (COEP) said Thursday that it received approval from the Nasdaq Hearings Panel to remain listed on Nasdaq through Jan. 15, 2025.
The company was granted a Nasdaq listing extension after presenting a plan, including a reverse stock split, to address the minimum bid price requirement.
Nasdaq issued a notice of non-compliance with the minimum bid price requirement on Jan. 29, 2024.
Price: 0.2040, Change: +0.03, Percent Change: +16.24
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。